Literature DB >> 1963547

Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival.

C M Tsai1, D C Ihde, C Kadoyama, D Venzon, A F Gazdar.   

Abstract

In vitro drug sensitivity testing (DST) of long-term cultures from small cell lung cancer (SCLC) tumours was correlated with response and survival after four cycles of etoposide and cisplatin. 27 cell lines from 25 patients were tested by the semi-automated MTT assay after a median culture of 29 months. The logs of the IC50 concentrations for etoposide and cisplatin were correlated with each other. For both drugs, median IC50 values of patients with partial or complete responses ("responders") were significantly lower (7-8 fold) than those of non-responders. When survival was plotted according to whether drug IC50 values were in the upper or lower halves, curves for etoposide were significantly different, but those of cisplatin were not. DST of the long-term cell lines by MTT assay was significantly correlated with the Weisenthal dye exclusion assay of earlier passages of the same cell lines. DST of long-term SCLC cultures can predict clinical response and, for etoposide, survival. Disease-oriented panels of carefully selected, continuous, human tumour cell lines can be used to screen new drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963547     DOI: 10.1016/0277-5379(90)90274-w

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.

Authors:  Ahmad Raza; Blake A Jacobson; Adam Benoit; Manish R Patel; Joe Jay-Dixon; Hiroshi Hiasa; David M Ferguson; Robert Arthur Kratzke
Journal:  Invest New Drugs       Date:  2011-07-26       Impact factor: 3.850

2.  Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.

Authors:  E J Derbyshire; R V Henry; R A Stahel; E J Wawrzynczak
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

3.  In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.

Authors:  P B Jensen; B Holm; M Sorensen; I J Christensen; M Sehested
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

Authors:  P B Jensen; I J Christensen; M Sehested; H H Hansen; L Vindeløv
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.